- Home
- ESTA vs JANX Comparison
ESTA vs JANX Comparison
Compare ESTA & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESTA | JANX |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Costa Rica | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ESTA | JANX |
|---|---|---|
| Price | $70.68 | $16.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $68.29 | $62.00 |
| AVG Volume (30 Days) | 517.5K | ★ 2.3M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,973,000.00 | $10,000,000.00 |
| Revenue This Year | $29.25 | N/A |
| Revenue Next Year | $24.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.76 | N/A |
| 52 Week Low | $26.56 | $15.51 |
| 52 Week High | $73.19 | $71.71 |
Technical Indicators
Market Signals| Indicator | ESTA | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 69.18 | 29.81 |
| Support Level | $62.77 | $15.51 |
| Resistance Level | $69.69 | $35.34 |
| Average True Range (ATR) | 3.22 | 1.91 |
| MACD | -0.43 | -1.87 |
| Stochastic Oscillator | 77.82 | 4.34 |
Price Performance
Historical ComparisonAbout ESTA Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.